For Immediate Release

Contact:

James Heins Senior Director Purdue Pharma L.P. 203-588-8069

Tom Rovine Cooney Waters Group 212-886-2200

Stamford, CT - March 10, 2008 – Purdue Pharma L.P. today announced that OxyContin® (oxycodone HCl controlled release) Tablets are now available in three new dosage strengths: 15 mg, 30 mg and 60 mg. These tablet strengths complement the currently available 10 mg, 20 mg, 40 mg and 80 mg dosages. The new tablet strengths are being introduced in response to requests from healthcare professionals for greater flexibility in dosing and titration for patients who are prescribed OxyContin Tablets.

"These new tablet strengths provide more options to prescribers to meet the individual therapeutic needs of their appropriate patients," said Craig Landau, MD, Vice President and Chief Medical Officer at Purdue Pharma L.P.

The availability of these new strengths has the potential to reduce the need for multiple prescriptions, and corresponding patient co-payments, as well as reduce the number of tablets needed to achieve a specific therapeutic dose. OxyContin should be individually titrated to a dose that provides adequate analgesia and minimal side effects. It is most appropriate to increase the q12h dose, not the dosing frequency. The need for around the clock opioid therapy should be reassessed periodically (e.g., every 6 to 12 months) as appropriate for patients on chronic therapy.

Shipment of the new tablet strengths to wholesale and retail customers began January 29, 2008. Purdue representatives are providing healthcare professionals with updated prescribing information to support appropriate use of these new tablet strengths.

Generic Versions of OxyContin Tablets Withdrawn
Purdue previously issued a statement that as of February 1, 2008, Teva Pharmaceuticals USA, Inc., IMPAX Laboratories, Inc. and IMPAX’s distributor DAVA Pharmaceuticals, Inc. have ceased distribution and sales of their generic versions of this medication pursuant to the terms of their licensing agreements with Purdue. On December 31, 2006, Endo Pharmaceuticals ceased distribution of its generic version of OxyContin pursuant to its license with Purdue. The licenses granted to Teva, IMPAX and Endo Pharmaceuticals preceded the January 7, 2008 decision of the United States District Court for the Southern District of New York in which the court ruled that Purdue Pharma had not committed inequitable conduct in obtaining its OxyContin patents and that its patents are not unenforceable for that reason. The last of Purdue’s patents on OxyContin Tablets expires April 2013. Purdue expects to be able to meet all demand for long-acting oxycodone prescriptions.

Patient Assistance
Except where prohibited by state or federal law or healthcare insurers, Purdue is offering patient savings cards through physicians to help reduce patients’ out-of-pocket costs. Purdue’s patient assistance program will continue to provide assistance to eligible low-income individuals who do not have healthcare insurance.

About Purdue Pharma L.P.
Purdue Pharma L.P. and its associated U.S. companies are privately-held pharmaceutical companies known for pioneering research on persistent pain. Headquartered in Stamford, CT, Purdue is engaged in the research, development, production, and distribution of both prescription and over-the-counter medicines and hospital products. Additional information about Purdue can be found at www.purduepharma.com.

The professional product labeling for OxyContin^® Tablets contains the following boxed warning:

Full prescribing information for OxyContin is available at
http://www.purduepharma.com/PI/Prescription/Oxycontin.pdf.

# # #